phenyl butazone
Notes :
a butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. it has been used in ankylosing spondylitis; rheumatoid arthritis; and reactive arthritis.
  • Home
  • Suppliers
  • Organoleptics
      • Organoleptic Properties
  • Properties
      • Physical Properties
        Appearance :white crystalline powder (est)
        Assay : 95.00 to 100.00 % 
        Food Chemicals Codex Listed :No
        Melting Point : 105.00 °C. @ 760.00 mm Hg
        Boiling Point : 424.89 °C. @ 760.00 mm Hg (est)
        Vapor Pressure :6.380000 mm/Hg @ 25.00 °C. (est)
        Flash Point : 346.00 °F. TCC ( 174.30 °C. ) (est)
        logP (o/w) : 3.160
  • Safety
      • Safety Information
        Oral/Parenteral Toxicity : 
          intravenous-cat LD50  100 mg/kg
        Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 36, 1969.

        intravenous-dog LD50  121 mg/kg
        BEHAVIORAL: ANALGESIA
        Archives Internationales de Pharmacodynamie et de Therapie. Vol. 149, Pg. 571, 1964.

        oral-dog LD50  332 mg/kg
        BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA
        Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 265, 1980.

        oral-guinea pig LD50  250 mg/kg
        Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 1207, 1969.

        oral-hamster LD50  1260 mg/kg
        Archives of Toxicology, Supplement. Vol. 7, Pg. 365, 1984.

        intraperitoneal-mammal (species unspecified) LD50  300 mg/kg
        BEHAVIORAL: ANALGESIA
        European Journal of Medicinal Chemistry--Chimie Therapeutique. Vol. 21, Pg. 277, 1986.

        oral-mammal (species unspecified) LD50  700 mg/kg
        BEHAVIORAL: ANALGESIA
        European Journal of Medicinal Chemistry--Chimie Therapeutique. Vol. 21, Pg. 277, 1986.

        oral-man TDLo  17500 ug/kg/3W
        KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED
        Annals of Internal Medicine. Vol. 41, Pg. 1075, 1954.

        oral-man TDLo  2426 mg/kg/24H
        LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
        Annals of Emergency Medicine. Vol. 20, Pg. 204, 1991.

        unreported-man TDLo  200 mg/kg/5W-I
        KIDNEY, URETER, AND BLADDER: HEMATURIA KIDNEY, URETER, AND BLADDER: URINE VOLUME DECREASED VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION
        British Medical Journal. Vol. 282, Pg. 950, 1981.

        intramuscular-mouse LD50  430 mg/kg
        BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
        Oyo Yakuri. Pharmacometrics. Vol. 13, Pg. 97, 1977.

        intraperitoneal-mouse LD50  128 mg/kg
        Pharmaceutical Chemistry Journal Vol. 19, Pg. 33, 1985.

        intravenous-mouse LD50  90 mg/kg
        Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 36, 1969.

        oral-mouse LD50  238 mg/kg
        Pharmacological Research Communications. Vol. 18, Pg. 241, 1986.

        unreported-mouse LD50  128 mg/kg
        Farmatsevtichnii Zhurnal Vol. (5), Pg. 26, 1983.

        intravenous-rabbit LD50  146 mg/kg
        BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
        Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 129, 1960.

        oral-rabbit LD50  781 mg/kg
        BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: DYSPNEA
        Oyo Yakuri. Pharmacometrics. Vol. 20, Pg. 265, 1980.

        intramuscular-rat LD50  220 mg/kg
        Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 665, 1960.

        intraperitoneal-rat LD50  142 mg/kg
        Farmaco, Edizione Scientifica. Vol. 14, Pg. 347, 1959.

        intravenous-rat LD50  100 mg/kg
        Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 665, 1960.

        oral-rat LD50  245 mg/kg
        BEHAVIORAL: ANALGESIA
        Archives Internationales de Pharmacodynamie et de Therapie. Vol. 123, Pg. 48, 1959.

        Dermal Toxicity : 
          subcutaneous-mouse LD50 230 mg/kg
        Journal of Pharmacy and Pharmacology. Vol. 7, Pg. 1022, 1955.

        subcutaneous-rat LD50 230 mg/kg
        BEHAVIORAL: TREMOR BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
        Oyo Yakuri. Pharmacometrics. Vol. 6, Pg. 1285, 1972.

        Inhalation Toxicity : 
          Not determined
  • Safety in Use
      • Safety in Use Information
        Category :pharmaceuticals / chemical synthisis
        Recommendation for phenyl butazone fragrance usage levels up to :
         not for fragrance use.
        Recommendation for phenyl butazone flavor usage levels up to :
         not for flavor use.
  • Safety References
  • Articles
      • Articles for the Flavor and Fragrance Industries
        Info :Phenylbutazone
  • References
      • References
         4- butyl-1,2-diphenylpyrazolidine-3,5-dione
        NIST Chemistry WebBook :Search Inchi
        Canada Domestic Sub. List :50-33-9
        Pubchem (cid):4781
        Pubchem (sid):134971182
  • Other
      • Other Information
        (IUPAC) :Atomic Weights of the Elements 2009
        (IUPAC) :Atomic Weights of the Elements 2009 (pdf)
        Videos :The Periodic Table of Videos
        tgsc :Atomic Weights use for this web site
        (IUPAC) :Periodic Table of the Elements
        CHEBI :View
        CHEMBL :View
        Export Tariff Code :2933.19.4000
        MedlinePlusSupp : View
        ChemSpider : View
        Wikipedia : View
        RSC Learn Chemistry : View
        Formulations/Preparations :
        •phenylbutazone tablets containing 100 mg and 1000 mg of active ingredient are available for oral administration to dogs and horses, respectively, for treatment of inflammation associated with the musculoskeletal system. phenylbutazone solution for intravenous injection contains 200 mgml of active ingredient and is indicated for the relief of inflammation associated with the musculoskeletal system of the horse. •grade: national formulary •oral capsules, 100 mg; phenylbutazone capsules, barr, cmc, interstate, major, rugby; tablets film-coated, 100 mg; phenylbutazone tablets, barr, cmc, interstate, major, rugby, united research.
  • Blenders
      • Potential Blenders and core components note
        None Found
  • Uses
      • Potential Uses
        None Found
  • Occurrence
      • Natural Occurrence in : note
         not found in nature
  • Search
      • Search for Name, Cas,
        Enics, Fema, Flavis
        Search for
        jecfa
        Search for
        Odor
4-butyl-1,2-diphenylpyrazolidine-3,5-dione (Click)
CAS Number : 50-33-9 4297-92-1
ESIS EC# (EINECS) :200-029-0
Beilstein Number :0290080
XlogP3 :3.20 (est)
Molecular Weight :308.38080000
Formula :C19 H20 N2 O2
BioActivity Summary :listing
NMR Predictor :Predict
Category :pharmaceuticals / chemical synthisis
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information :
Google Scholar : Search Google Books : Search
Google Scholar : with word "volatile"Search Google Scholar : with word "flavor"Search
Google Scholar : with word "odor"Search 
Google Patents : Search US Patents : Search
EU Patents : Search
Pubchem Patents:Search
PubMed : SearchNCBI : Search
click on the picture(s) below to
interact with the 3D model
Picture of molecule
4-butyl-1,2-diphenylpyrazolidine-3,5-dione
Synonyms :
4-butyl-1,2 -diphenyl-3,5-dioxo pyrazolidine
4-butyl-1,2-diphenyl-1,2-diazolidine-3,5-dione
4-butyl-1,2-diphenyl-3,5-dioxopyrazolidine
4-butyl-1,2-diphenyl-3,5-pyrazolidinedione
4-N-butyl-1,2-diphenyl-3,5-pyrazolidinedione
4-butyl-1,2-diphenyl-pyrazolidine-3,5-dione
4-butyl-1,2-diphenylpyrazolidine-3,5-dione
3,5-dioxo-1,2-diphenyl-4-N-butylpyrazolidine
3,5-dioxo-4-butyl-1-diphenyl-pyrazolidine
1,2-diphenyl-2,3-dioxo-4-N-butylpyrazoline
1,2-diphenyl-3,5-dioxo-4-butylpyrazolidine
1,2-diphenyl-3,5-dioxo-4-N-butylpyrazoline
1,2-diphenyl-4-butyl-3,5-dioxopyrazolidine
1,2-diphenyl-4-butyl-3,5-pyrazolidinedione
 mepha-butazon
 phenbutazone
 phenylbutazone
 phenylbutazonum
 phenyzene
 pyrasanone
 pyrazinobutazone
3,5-pyrazolidinedione, 4-butyl-1,2-diphenyl-
 Ranoroc
 shigrodin
 tencodyne
 tetnor
 tevcodyne
 therazone
 ticinil
 todalgil
 zolidinum
Soluble in :
 water, 47.5 mg/L @ 30 °C (exp)
 water, 21.95 mg/L @ 25 °C (est)
Stability :
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2014 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy